Cell Therapy Bioprocessing Market Size, Share Forecast to 2028
The cell therapy bioprocessing is expected to reach US$ 30,052.61 million in 2028 from US$ 11,192.50 million in 2020. The market is estimated to grow with a CAGR of 13.5% from 2021-2028.
The cell therapy bioprocessing market has been analyzed on the basis of technology, cell type, end user, and region. The market based on region is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. The report emphasizes on parameters such as market trends, technological advancements, market dynamics, and leading company’s competitive landscape analysis to offers insights and in-depth analysis of the cell therapy bioprocessing market. It also includes the analysis of COVID-19 pandemic across the market in all the key regions.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Cell Therapy Bioprocessing Market: Strategic Insights
Cell Therapy Bioprocessing Market
-
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cagr.png)
CAGR (2020 - 2028)
13.5%
-
Market Size 2020
US$ 11.19 Billion
-
Market Size 2028
US$ 30.05 Billion
Market Dynamics
GROWTH DRIVERS
- XXXXXXX
- XXXXXXX
- XXXXXXX
FUTURE TRENDS
- XXXXXXX
- XXXXXXX
- XXXXXXX
OPPORTUNITIES
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- Fresenius Kabi AG
- Asahi Kasei Corporation
- Sartorius AG
- MERCK KGaA
- THERMO FISHER SCIENTIFIC INC.
- Corning Incorporated
- Cytiva
- Lonza
- Repligen
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Product Type
- Technology
- Cell Type
Indication
- Cardiovascular Disease
Oncology, Wound Healing, Orthopedic, Others)
End user
- Hospitals and Clinics
- Diagnostic Centers
- Regenerative Medicine Centers
- Academic and Research Institute
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Cell Therapy Bioprocessing Market: Strategic Insights
-
CAGR (2020 - 2028)13.5% -
Market Size 2020
US$ 11.19 Billion -
Market Size 2028
US$ 30.05 Billion
![](https://www.theinsightpartners.com/assets/images/rd_int_img/tip-logo.jpg)
Market Dynamics
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
Key Players
- Fresenius Kabi AG
- Asahi Kasei Corporation
- Sartorius AG
- MERCK KGaA
- THERMO FISHER SCIENTIFIC INC.
- Corning Incorporated
- Cytiva
- Lonza
- Repligen
Regional Overview
![](https://www.theinsightpartners.com/assets/images/rd_int_img/ig-regional.png)
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_danger.png)
- Technology
- Cell Type
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_warning.png)
- Cardiovascular Disease
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_primary.png)
![](https://www.theinsightpartners.com/assets/images/rd_int_img/cust_bullet_warning.png)
- Hospitals and Clinics
- Diagnostic Centers
- Regenerative Medicine Centers
- Academic and Research Institute
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Market Insights
Growing Approvals for Cell Therapies
Cell therapies have shown positive results in treating various chronic diseases including rare genetic disorders by offering regenerative medicines and personalized medicines. Increasing need of treating chronic diseases have pushed the research and development activities resulting in growing cell therapy production and product approvals. Few instances are listed below for the cell therapies approvals that have contributed to the growth of the cell therapy bioprocessing market.
- In May 2019, the Food and Drug Administration (FDA) approved Zolgensma, manufactured by AveXis, Inc. A subsidiary of Novartis AG. Zolgensa is designed to treat spinal muscular atrophy in children below two years and is given by infusing one-time into the vein.
- In July 2020, Kite Pharma, Inc., a Subsidiary of Gilead Company, received FDA approval for its Tecartus. Tecartus is (CAR) T cell therapy designed to treat refractory mantle cell lymphoma (MCL) in adults. According to toe Gilead Company, Tecartus is the first approved (CAR) T cell therapy for mantle cell lymphoma, which is expected to be a new frontier in the treatment of mantle cell lymphoma.
- In February 2021, Juno Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb Company, received approval for its Breyanzi. Breyanzi is a cell-based gene therapy intended to treat certain types of large B-cell lymphoma in adults. The treatment is given after patient have not responded to minimum two other types of systemic treatment. However, Breyanzi in 2019, faced regulatory setback since its first filing; it is currently under the European Medicines Agency’s review and was validated in July 2020.
Thus, growing product developments have resulted in various product approvals that reflects the increase in cell therapies. Therefore, it is expected that the growing approvals for cell therapies are enormously increasing the cell therapy bioprocessing, which, in turn is likely to drive the market’s growth over the coming years
Technology-Based Insights
The cell therapy bioprocessing market, by technology, is segmented into bioreactor, lyophilization, electro spinning, controlflow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. The Bioreactor segment held the largest share of the market in 2020, whereas the genome editing technology segment is anticipated to register the highest CAGR of 14.5% in the market during the forecast period.
Cell Type-Based Insights
The cell therapy bioprocessing market, by cell type, is segmented into stem cell, immune cell, human embryonic stem cell, pluripotent stem cell, hematopoietic stem cells. The stem cell segment held the largest share of the market in 2020, whereas the same segment is anticipated to register the highest CAGR of 14.0% in the market during the forecast period.
End User-Based Insights
The cell therapy bioprocessing market, by indication, is segmented cardiovascular disease (CVD), oncology, wound healing, orthopedic, and others. The oncology segment held the largest share of the market in 2020, and the orthopedic segment is anticipated to register the highest CAGR of 14.3% in the market during the forecast period.
Companies operating in the cell therapy bioprocessing market are adopting organic strategies such as product launches and expansions to expand their footprint and product portfolio worldwide as well as to address the growing demands.
Cell Therapy Bioprocessing Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2020 | US$ 11.19 Billion |
Market Size by 2028 | US$ 30.05 Billion |
Global CAGR (2020 - 2028) | 13.5% |
Historical Data | 2018-2019 |
Forecast period | 2021-2028 |
Segments Covered |
By Product Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
By Technology
- Bioreactor
- Lyophilization
- Electrospinning
- Controlflow Centrifugation
- Ultrasonic Lysis
- Genome Editing Technology
- Cell Immortalization Technology
- Viral Vector Technology
By Cell Type
- Stem Cell
- Immune Cell
- Human Embryonic Stem Cell
- Pluripotent Stem Cell
- Hematopoetic Stem Cell
By Indication
- Cardiovascular Disease (CVD)
- Oncology
- Wound Healing
- Orthopedic
- Others
By End User
- Hospitals and Clinics
- Diagnostic Centers
- Regenerative Medicine Centers
- Academic and Research Institute
By Geography
North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of APAC
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Company Profiles
- Fresenius Kabi AG
- Asahi Kasei Corporation
- Sartorius AG
- MERCK KGaA
- THERMO FISHER SCIENTIFIC INC.
- Corning Incorporated
- Cytiva
- Lonza
- Repligen
- Catalent Inc
![Report Coverage](https://www.theinsightpartners.com/assets/rdimages/report_coverage.png)
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
![Segment Covered](https://www.theinsightpartners.com/assets/rdimages/segment_covered.png)
Segment Covered
Product Type ; Indication ; End user
![Regional Scope](https://www.theinsightpartners.com/assets/rdimages/regional_scope.png)
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
![Country Scope](https://www.theinsightpartners.com/assets/rdimages/country_scope.png)
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The costs of the Cell Therapy Bioprocessing are much higher, and they may cost US$ 50,000–100,000, or more, per cell therapy. The cost may also differ from product to product types.
Key factors driving the growth of the market are increasing investments for cell and gene therapy manufacturing, and growing approvals for cell therapies are the major factors driving the market growth. However, challenges such as high cost of product, regulatory challenges, and logistics challenges are likely to hinder the growth of the cell therapy bioprocessing market.
Cell therapy bioprocessing is a subfield of bioprocess engineering that bridges cell therapy and bioprocessing (i.e., biopharmaceutical manufacturing). Cell therapy is one of the fastest-growing areas of the life sciences. It entails delivering entire living cells to a patient to treat disease.
The List of Companies - Cell Therapy Bioprocessing Market
- Fresenius Kabi AG
- Asahi Kasei Corporation
- Sartorius AG
- MERCK KGaA
- THERMO FISHER SCIENTIFIC INC.
- Corning Incorporated
- Cytiva
- Lonza
- Repligen
- Catalent Inc